ye
histor
discoveri
sulfa
drug
subsequ
develop
penicillin
world
war
ii
usher
new
era
treatment
infecti
diseas
infect
common
caus
death
diseas
preantibiot
era
rheumat
fever
syphili
cellul
bacteri
pneumonia
becam
treatabl
next
year
class
antibiot
find
clinic
use
today
discov
chang
medicin
profound
way
avail
antibiot
enabl
revolutionari
medic
intervent
cancer
chemotherapi
organ
transplant
essenti
major
invas
surgeri
joint
replac
coronari
bypass
antibiot
though
uniqu
among
drug
use
precipit
obsolesc
paradox
cure
select
organ
evad
fuel
arm
race
microb
clinician
drug
discover
antibiot
target
essenti
bacteri
physiolog
biochemistri
caus
microbi
cell
death
cessat
growth
five
major
antibiot
target
bacteri
cell
wall
cell
membran
protein
synthesi
dna
rna
synthesi
folic
acid
vitamin
metabol
figur
bacteri
target
differ
nonexist
eukaryot
cell
includ
human
mean
antibiot
rel
nontox
drug
exampl
antibiot
penicillin
cephalosporin
carbapenem
block
synthesi
bacteri
cell
wall
structur
absent
higher
organ
essenti
bacteri
surviv
bacteri
ribosom
target
tetracyclin
aminoglycosid
macrolid
antibiot
suffici
differ
eukaryot
ribosom
crossinhibit
occur
resist
antibiot
occur
four
gener
mechan
target
modif
efflux
immun
bypass
enzymecatalyz
destruct
figur
target
modif
occur
mutat
target
exampl
topoisomeras
target
fluoroquinolon
antibiot
product
enzym
modifi
antibiot
target
exampl
ribosom
methyl
vancomycin
resist
version
target
modif
new
biosynthet
machineri
engag
alter
cellwal
structur
efflux
occur
larg
famili
protein
pump
eject
antibiot
insid
cell
immun
antibiot
target
bound
protein
prevent
antibiot
bind
target
arguabl
specif
evolv
mechan
antibiot
resist
enzym
recogn
antibiot
modifi
way
elimin
function
characterist
enabl
interact
target
exampl
hydrolyt
cleav
core
ring
characterist
class
essenti
antibiot
action
resist
antibiot
record
even
first
clinic
use
penicillin
earli
interven
year
resist
class
antibiot
emerg
antibiot
resist
exist
two
gener
strategi
resist
one
compris
mechan
transfer
resist
vertic
bacterium
progeni
exampl
mutat
chromosom
gene
give
rise
druginsensit
product
point
mutat
gene
encod
dna
gyras
topoisomeras
iv
result
resist
fluoroquinolon
antibiot
ciprofloxacin
second
strategi
includ
action
gene
transmit
vertic
progeni
horizont
bacteria
even
differ
genera
gene
locat
mobil
genet
element
plasmid
carri
one
resist
gene
mani
gene
confer
resist
penicillin
cephalosporin
penem
monobactam
antibiot
locat
element
glycopeptideresist
gene
cluster
vanhax
provid
resist
vancomycin
preval
mobil
resist
gene
previous
sensit
pathogen
bacteria
reach
crisi
level
mani
case
new
antibiot
longer
develop
rate
keep
pace
microbi
evolut
past
two
decad
wit
rise
socal
extend
spectrum
esbl
mutant
enzym
previous
could
inactiv
penicillin
gain
activ
mani
cephalosporin
carbapenemas
kpc
inactiv
antibiot
plasmidmedi
thu
horizont
dissemin
resist
fluoroquinolon
antibiot
spread
virul
mrsa
methicillinresist
staphylococcu
aureu
commun
rise
multidrug
resist
neisseria
gonorrhoea
emerg
global
dissemin
multidrug
resist
acinetobact
baumannii
pseudomona
aeruginosa
klebsiella
pneumonia
enterobacteriacea
spread
extens
drug
resist
mycobacterium
tuberculosi
develop
resist
two
newest
antibiot
approv
clinic
use
daptomycin
linezolid
resist
relentless
unavoid
long
use
antibiot
antibiot
resist
evolutionari
respons
strong
select
pressur
result
exposur
compound
horizont
dissemin
resist
gene
bacteri
speci
genera
intrins
resist
well
mainten
resist
mutat
vertic
popul
like
result
contemporari
use
drug
clinic
farm
support
hypothesi
infrequ
antibiot
resist
collect
pathogen
bacteria
predat
antibiot
era
nevertheless
antibiot
resist
natur
phenomenon
recogn
decad
resist
mechan
emerg
clinic
parallel
intrins
bacteria
produc
antibiot
recent
studi
nonpathogen
soil
bacteria
reveal
major
environment
bacteria
test
multidrug
resist
reflect
fact
microb
live
evolv
environ
small
bioactiv
molecul
toxic
benign
plenti
divers
bacteria
simpli
evolv
interact
control
biolog
effect
pathogen
hand
often
virul
form
commens
bacteria
simpli
expos
divers
type
small
molecul
found
environ
result
requir
gamut
resist
gene
found
environment
bacteria
furthermor
gene
protein
respons
resist
environment
bacteria
homolog
found
circul
pathogen
strongli
suggest
contemporari
horizont
gene
transfer
opportunist
pathogen
environment
reservoir
exampl
p
aeruginosa
baumannii
highli
drug
resist
remark
capac
acquir
new
resist
gene
environ
therefor
larg
reservoir
potenti
resist
gene
environment
resistom
given
vast
number
bacteria
planet
massiv
select
pressur
provid
antibiot
movement
antibioticresist
element
benign
resist
microb
previous
suscept
pathogen
simpli
matter
time
opportun
antibiot
sourc
evolutionari
pressur
eventu
render
obsolet
limit
exposur
microb
antibiot
therefor
make
good
sens
reduc
opportun
select
dissemin
resist
inappropri
use
antibiot
clinician
agricultur
commun
need
curtail
past
sever
year
medic
commun
particular
made
concret
effort
curb
improp
use
antibiot
european
union
taken
lead
limit
nontherapeut
use
antibiot
food
anim
robust
surveil
network
span
clinic
farm
need
support
order
monitor
impact
resist
emerg
new
threat
real
time
north
america
effort
strategi
address
antimicrobi
resist
act
seek
diminish
antibiot
use
agricultur
improv
surveil
furthermor
sever
success
campaign
educ
public
import
antibiot
proper
use
drug
none
effort
perfect
much
celebr
encourag
measur
serv
reduc
antibiot
use
result
delay
emerg
resist
furthermor
decreas
select
pressur
opportun
rise
particularli
clinic
challeng
virul
organ
lessen
strategi
reduc
incorrect
use
antibiot
welcom
end
new
drug
alway
need
inevit
resist
unfortun
develop
world
access
antibiot
frequent
regul
use
agricultur
often
rampant
fact
make
antibiot
stewardship
especi
challeng
era
rapid
intercontinent
travel
pathogen
longer
geograph
contain
move
countri
countri
eas
recent
exampl
transcontinent
spread
sever
acut
respiratori
syndrom
sar
viru
guangdong
provinc
china
hong
kong
canada
carbapenemas
inactiv
antibiot
appear
origin
indian
subcontin
found
north
america
uk
europ
make
point
grow
problem
resist
fuel
continu
need
new
antibiot
drug
enterobacteria
produc
carbapenemas
one
exampl
antibioticresist
enterobacteria
gramneg
pathogen
resist
virtual
antibiot
includ
multidrug
resist
baumannii
p
aeruginosa
expand
problem
mrsa
global
challeng
extens
drugresist
tuberculosi
also
call
extrem
drugresist
tuberculosi
requir
new
therapi
promis
new
candid
horizon
especi
treatment
infect
caus
gramposit
pathogen
mrsa
enterococci
alreadi
mention
two
new
drug
activ
microbi
spectrum
daptomycin
linezolid
introduc
past
decad
tigecyclin
thirdgener
semisynthet
tetracyclin
antibiot
approv
also
activ
mrsa
semisynthet
glycopeptid
antibiot
telavancin
recent
receiv
approv
unit
state
fifthgener
cephalosporin
ceftobiprol
avail
european
countri
canada
howev
candid
latestag
clinic
trial
suitabl
problem
gramneg
pathogen
often
choic
last
resort
colistin
antibiot
discov
year
ago
seldom
use
past
advers
affect
includ
kidney
toxic
howev
increasingli
use
number
reason
econom
pauciti
new
antibiot
includ
challeng
shift
process
govern
regulatori
approv
add
risk
pharmaceut
industri
furthermor
consider
return
invest
favor
drug
chronic
diseas
taken
patient
long
period
time
often
decad
contrast
antibiot
cure
diseas
taken
short
period
time
reason
declin
antibiot
discoveri
develop
scientif
first
wave
antibiot
discov
five
decad
ago
term
low
hang
fruit
despit
discoveri
numer
compound
antibiot
properti
year
sinc
requisit
properti
becom
drug
antibiot
natur
product
deriv
isol
soil
bacteria
research
suggest
sourc
might
exhaust
furthermor
promis
genom
era
realiti
hundr
avail
bacteri
genom
far
fail
deliv
hopedfor
new
molecular
target
antibiot
new
technolog
highthroughput
screen
librari
synthet
molecul
result
new
drug
although
may
reflect
poor
choic
chemic
class
screen
emphas
molecul
activ
human
biolog
antibiot
test
compound
often
skew
favor
small
lipophil
molecul
physic
properti
meet
criteria
lipinski
rule
howev
though
help
assess
prospect
compound
oral
activ
drug
human
diseas
strategi
shown
fail
search
antibiot
well
natur
chemic
signific
advantag
although
first
antibiot
introduc
clinic
synthet
sulfonamid
major
antibiot
current
clinic
use
bacteri
produc
natur
product
deriv
complet
synthet
origin
reason
part
reflect
histori
antibiot
discoveri
postpenicillin
rel
eas
discoveri
suitabl
molecul
screen
product
soil
microb
compar
librari
synthet
compound
mani
natur
antibiot
desir
druglik
qualiti
good
bioavail
abil
cross
cell
membran
outer
membran
case
compound
gramneg
activ
abil
evad
efflux
system
chemic
structur
favor
bind
vital
cellular
target
support
idea
natur
product
encompass
privileg
structur
antibiot
drug
discoveri
howev
increas
difficulti
identifi
new
chemic
compound
equal
suitabl
druglik
characterist
natur
sourc
caus
naturalproductbas
screen
program
fall
favor
mani
pharmaceut
firm
past
decad
instead
abil
parallel
synthesi
method
gener
hundr
thousand
synthet
molecul
suitabl
modern
highthroughput
screen
shift
focu
favor
synthet
molecul
commerci
antibacteri
drug
discoveri
advantag
synthet
compound
insignific
pure
lead
molecul
easili
produc
quantiti
qualiti
suitabl
clinic
trial
rel
easili
modifi
improv
target
affin
howev
two
three
decad
emphasi
molecul
million
dollar
spent
highthroughput
vitro
cellbas
screen
new
synthet
antibiot
emerg
linezolid
one
synthet
antibiot
brought
market
past
decad
discov
use
tradit
medicin
chemistri
research
program
plantdiseas
focu
earli
great
advantag
although
direct
comparison
success
failur
synthet
natur
product
librari
unfair
microbi
natur
product
evolv
millennia
interact
biolog
molecul
wherea
synthet
chemic
librari
use
antibiot
drugdiscoveri
screen
gener
develop
focu
eukaryot
drugdiscoveri
campaign
note
earlier
effort
develop
physicalproperti
rule
antibiot
incorpor
naturalproductlik
chemic
complex
librari
synthet
chemic
doubt
improv
success
identifi
new
synthet
antibiot
lead
iron
time
pharmaceut
industri
abandon
naturalproduct
librari
univers
research
make
remark
advanc
understand
molecular
detail
naturalproduct
biosynthesi
bacteria
mani
bacteria
especi
actinomycet
group
common
environment
bacteria
prodigi
produc
natur
product
term
secondari
metabolit
contrast
molecul
primari
metabol
carbohydr
amino
acid
secondari
metabolit
rang
molecular
weight
around
dalton
da
da
divers
biolog
activ
includ
induct
cell
death
antibiot
tetracyclin
vancomycin
daptomycin
anticanc
agent
adriamycin
iron
sequestr
exampl
enterobactin
facilit
cellcel
commun
protect
oxid
agent
phenazin
host
other
bacteri
natur
product
import
antibiot
includ
polyketid
macrolid
tetracyclin
nonribosom
peptid
peptid
synthes
ribosom
includ
glycopeptid
vancomycin
produc
cell
assemblylin
fashion
larg
dedic
enzym
platform
call
respect
polyketid
synthas
nonribosom
peptid
synthetas
follow
assembl
compound
decor
seri
modifi
enzym
glycosyltransferas
end
result
molecul
often
complex
structur
multipl
chiral
center
function
group
sugar
halogen
sulfat
acyl
group
other
gener
bacteri
gene
encod
product
natur
product
cluster
togeth
genom
greatli
facilit
analysi
predict
biosynthet
pathway
structur
inde
sever
softwar
packag
exampl
np
searcher
develop
base
rulesbas
understand
naturalproduct
biosynthesi
avail
cheap
rapid
genom
sequenc
mean
timeconsum
construct
screen
gene
librari
naturalproduct
cluster
bypass
genom
sequenc
also
reveal
hitherto
unreal
rich
quantiti
variabl
naturalproduct
biosynthet
cluster
sequenc
genom
bacteria
actinomycet
class
reveal
biosynthet
cluster
organ
furthermor
naturalproduct
produc
bacteria
nonsoil
environ
investig
alreadi
result
new
chemic
matter
suggest
fantast
wealth
untap
chemic
divers
wait
discov
perhap
divers
includ
new
antibiot
chemic
scaffold
remark
product
time
naturalproduct
research
serv
reinvigor
interest
sector
time
applic
synthet
biolog
approach
field
could
serv
improv
issu
yield
expand
chemic
divers
ye
first
exist
discard
antibiot
reexamin
develop
daptomycin
instruct
daptomycin
discov
antibiot
group
eli
lilli
fulli
develop
toxic
concern
antibiot
obtain
research
cubist
alter
dose
group
abl
bring
antibiot
market
sinc
prove
highli
success
treat
infect
caus
gramposit
pathogen
certainli
old
antibiot
discov
pharmaceut
industri
develop
time
could
resurrect
lead
new
drug
second
option
combin
antibiot
drug
improv
efficaci
infectiousdiseas
physician
often
combin
antibiot
effort
achiev
synergi
wellestablish
practic
result
formul
drug
combin
cotrimoxazol
trimethoprim
sulfamethoxazol
combin
antibiot
nonantibiot
deserv
investig
well
sever
natur
product
discov
satoshi
omura
group
potenti
activ
antibiot
imipenem
aureu
unknown
mechan
antibiot
adjuv
inhibitor
resist
mechan
tremend
commerci
clinic
success
augmentin
ampicillin
togeth
inhibitor
clavulan
acid
similar
combin
speak
power
combin
grow
understand
mechan
resist
fuel
approach
inhibitor
efflux
pump
exampl
discov
though
challeng
implement
organ
multipl
redund
system
worthi
continu
investig
final
strategi
orthogon
antibiot
must
tabl
never
forget
vaccin
proven
outstand
protect
agent
infecti
diseas
bacteri
virus
bacteriophag
use
extens
treat
bacteri
infect
former
soviet
union
could
find
new
applic
face
outbreak
multidrug
resist
bacteria
especi
set
hospit
infect
use
enhanc
innat
immun
cation
antimicrobi
peptid
also
approach
worth
investig
need
antibiot
maintain
current
standard
health
care
alreadi
state
resist
natur
evolutionari
phenomenon
stop
judici
use
current
drug
develop
new
one
pace
resist
develop
control
without
impair
abil
control
diseas
need
new
drug
howev
acut
antimicrobi
stewardship
alon
fulfil
requir
new
antibiot
remark
excit
time
fundament
research
antibiot
rapid
genom
sequenc
matur
knowledg
natur
product
biosynthesi
grow
understand
physic
properti
ideal
antibiot
develop
new
strategi
develop
synthet
compound
improv
antibiot
properti
possibl
synthet
biolog
combin
suggest
enter
highli
product
period
antibiot
discoveri
challeng
move
advanc
clinic
fast
enough
keep
pace
resist
signific
concert
effort
scientist
funder
industri
regul
clinician
believ
overcom
aria
ca
murray
antibioticresist
bug
centuri
clinic
superchalleng
n
engl
j
med
baquero
f
alvarezortega
c
martinez
jl
ecolog
evolut
antibiot
resist
env
microbiol
rep
boucher
hw
talbot
gh
bradley
js
edward
je
gilbert
rice
lb
scheld
spellberg
b
bartlett
j
bad
bug
drug
eskap
updat
infecti
diseas
societi
america
clin
infect
di
fenic
w
jensen
pr
develop
new
resourc
drug
discoveri
marin
actinomycet
bacteria
nat
chem
biol
fischbach
walsh
ct
antibiot
emerg
pathogen
scienc
kumarasami
kk
toleman
walsh
tr
bagaria
j
butt
f
balakrishnan
r
chaudhari
u
doumith
gisk
cg
irfan
krishnan
p
kumar
av
maharjan
mushtaq
noori
paterson
dl
pearson
perri
c
pike
r
rao
b
ray
u
sarma
jb
sharma
sheridan
e
thirunarayan
turton
j
upadhyay
warner
welfar
w
livermor
dm
woodford
n
emerg
new
antibiot
resist
mechan
india
pakistan
uk
molecular
biolog
epidemiolog
studi
lancet
infect
di
livermor
dm
era
untreat
infect
ariv
j
antimicrob
chemoth
suppl
shahid
sobia
f
singh
malik
khan
hm
jona
hawkey
pm
betalactam
betalactamaseinhibitor
current
potentialclin
practic
comprehens
updat
crit
rev
microbiol
wright
gd
antibiot
resistom
nexu
chemic
genet
divers
nat
rev
microbiol
yamazaki
h
nonaka
k
masuma
r
omura
tomoda
h
xanthoradon
new
potenti
imipenem
activ
methicillinresist
staphylococcu
aureu
produc
penicillium
radicum
taxonomi
ferment
isol
biolog
properti
j
antibiot
tokyo
infecti
diseas
societi
america
idsa
http
wwwidsocietyorg
